Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trialKeunchil Park, Luis Paz‐Ares, Ki Hyeong Lee et al.|The Lancet Oncology|2016Cited by 1.2k
American Society of Clinical Oncology Clinical Practice Guideline for the Use of Larynx-Preservation Strategies in the Treatment of Laryngeal CancerDavid G. Pfister, Gregory T. Wolf, Scott A. Laurie et al.|Journal of Clinical Oncology|2006Cited by 504
Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic reviewScott A. Laurie, David G. Pfister, Alan L. Ho et al.|The Lancet Oncology|2010Cited by 394
Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer: American Society of Clinical Oncology Clinical Practice Guideline UpdateArlene A. Forastiere, Gregory T. Wolf, Nofisat Ismaila et al.|Journal of Clinical Oncology|2017Cited by 366